Leukemia, Myelomonocytic, Chronic
Showing 26 - 50 of >10,000
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia
- +2 more
-
Duarte, California
- +1 more
Mar 14, 2023
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Trial in Houston (Decitabine and Cedazuridine, Venetoclax)
Recruiting
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Decitabine and Cedazuridine
- Venetoclax
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)
Recruiting
- Leukemia
- +2 more
- Enasidenib mesylat dose escalation
-
Palo Alto, CaliforniaStanford Cancer Institute
May 12, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)
Active, not recruiting
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
-
Baltimore, Maryland
- +3 more
Aug 8, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial (LP-108, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- (no location specified)
Nov 29, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Finland (Bexmarilimab, Azacitidine, Venetoclax)
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Bexmarilimab
- +2 more
-
Helsinki, Finland
- +3 more
Jun 29, 2022
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Rochester (Hyperbaric oxygen)
Recruiting
- Acute Myeloid Leukemia
- +6 more
- Hyperbaric oxygen
-
Rochester, New YorkWilmot Cancer Institute, University of Rochester
May 16, 2022
Azacitidine in International Prognostic Scoring System
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Hefei, Anhui, China
- +16 more
Sep 6, 2022
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston
Recruiting
- Chronic Myelomonocytic Leukemia
- +3 more
- Decitabine
- Tagraxofusp-erzs
-
Houston, TexasM D Anderson Cancer Center
Mar 4, 2022
MDS, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia Trial in Sydney (Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET,
Recruiting
- Myelodysplastic Syndromes
- +2 more
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET
- Defactinib
-
Sydney, New South Wales, Australia
- +3 more
Jan 12, 2023
Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia Trial in Toronto (Observational)
Recruiting
- Primary Myelofibrosis
- +9 more
- Observational
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 11, 2022
MDS, Secondary Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Aachen, Düsseldorf, Jena (Venetoclax, Amsacrine,
Not yet recruiting
- Myelodysplastic Syndromes
- +2 more
- Venetoclax
- +4 more
-
Aachen, NRW, Germany
- +2 more
Mar 29, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia Trial in United States (drug, procedure, other, radiation)
Not yet recruiting
- Acute Lymphoblastic Leukemia
- +10 more
- Busulfan
- +10 more
-
Jacksonville, Florida
- +5 more
Aug 14, 2023
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in
Suspended
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma Trial in Baltimore (Fludarabine,
Completed
- Myelodysplastic Syndrome
- +13 more
- Fludarabine
- +4 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nov 2, 2022
MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- decitabine
- +5 more
- (no location specified)
Aug 5, 2022
Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
- Imatinib Mesylate (Gleevec)
-
Houston, TexasUT MD Anderson Cancer Center
Dec 7, 2021
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia Trial in Chapel
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Biospecimen Collection
- +3 more
-
Baltimore, Maryland
- +2 more
Jan 19, 2023
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Boston (biological, procedure, drug)
Terminated
- Myelodysplastic Syndrome
- +2 more
- GVAX
- +6 more
-
Boston, Massachusetts
- +3 more
Jun 30, 2022
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,
Completed
- Chronic Myelomonocytic Leukemia
- +3 more
- Azacitidine
- +2 more
-
Scottsdale, Arizona
- +3 more
Jan 12, 2023